A New Quality Milestone
Bath ASU proudly marked a quality milestone last week with the successful validation and implementation of a new MALDI-TOF (Matrix-assisted laser desorption/ionisation time of flight) equipment.
The MALDI-TOF equipment rapidly and accurately identifies microorganisms that could be present in the compounding environment, ensuring the highest standards of safety and quality are upheld at Bath ASU.
“This new capability reflects our ongoing focus on innovation to drive important quality outcomes for our customers,” said Bath ASU Head of Quality, Cheryl Guite. “Compared to older traditional laboratory methods, the MALDI-TOF can provide microorganism identification in as little as 10 minutes rather than days. This enables our quality team to make swift interventions that support the integrity of our products.”
Bath ASU General Manager Kirsty Keith added: “The speed and accuracy of the MALDI-TOF gives our healthcare partners increased confidence in Bath ASU’s quality assurance processes, ultimately strengthening the service we provide for their patients.”
Icon Group Global CEO, Mark Middleton, joined the team onsite to officially launch the new equipment. This follows Bath ASU’s acquisition by Icon Group in 2024, who also own a large sterile manufacturer in Australia servicing 70% of the country’s chemotherapy needs.
The celebration served as a fitting reminder of Bath ASU’s role within Icon Group’s global network – innovating with cutting-edge technology to deliver the best patient outcomes for people across the UK.
